{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:38:49Z","timestamp":1787027929737,"version":"build-2736575974"},"reference-count":42,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Psoriatic disease (PsD) affects multiple clinical domains and causes a significant inflammatory burden in patients, requiring comprehensive evaluation and treatment. In recent years, new molecules such as JAK inhibitors (JAKinhibs) have been developed. These have very clear advantages: they act quickly, have a beneficial effect on pain, are well tolerated and the administration route is oral. Despite all this, there is still little scientific evidence in daily clinical practice. This observational, retrospective, single-center study was carried out in patients diagnosed with PsA in the last two years, who started treatment with Tofacitinib or Upadacitinib due to failure of a DMARD. The data of 32 patients were analyzed, and the majority of them (75%) started treatment with Tofacitinib. Most had moderate arthritis activity and mild psoriasis involvement according to activity indices. Both Tofacitinib and Upadacitinib demonstrated significant efficacy, with rapid and statistically significant improvement in joint and skin activity indices, C-reactive protein reduction, and objective measures of disease activity such as the number of painful and inflamed joints. Although there was some difference in the baseline characteristics of the cohort, treatment responses were comparable or even superior to those in the pivotal clinical trials. In addition, there was a low frequency of mild adverse events leading to treatment discontinuation and no serious adverse events. These findings emphasize the strong efficacy and tolerability of JAKinhibs in daily clinical practice, supporting their role as effective therapeutic options for patients with PsD.<\/jats:p>","DOI":"10.3390\/diagnostics14100988","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T13:20:24Z","timestamp":1715174424000},"page":"988","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["JAKinhibs in Psoriatic Disease: Analysis of the Efficacy\/Safety Profile in Daily Clinical Practice"],"prefix":"10.3390","volume":"14","author":[{"given":"Francesco","family":"Bizzarri","sequence":"first","affiliation":[{"name":"Servicio de Reumatologia, Instituto Biosanitario de Granada, Ibs, Hospital Universitario San Cecilio, 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-6174","authenticated-orcid":false,"given":"Ricardo","family":"Ruiz-Villaverde","sequence":"additional","affiliation":[{"name":"Servicio de Dermatolog\u00eda, Instituto Biosanitario de Granada, Ibs, Hospital Universitario San Cecilio, 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Morales-Garrido","sequence":"additional","affiliation":[{"name":"Servicio de Reumatologia, Instituto Biosanitario de Granada, Ibs, Hospital Universitario San Cecilio, 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Carlos","family":"Ruiz-Carrascosa","sequence":"additional","affiliation":[{"name":"Servicio de Dermatolog\u00eda, Instituto Biosanitario de Granada, Ibs, Hospital Universitario San Cecilio, 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-205X","authenticated-orcid":false,"given":"Marta","family":"Cebolla-Verdugo","sequence":"additional","affiliation":[{"name":"Servicio de Dermatolog\u00eda, Instituto Biosanitario de Granada, Ibs, Hospital Universitario San Cecilio, 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6799-3727","authenticated-orcid":false,"given":"Alvaro","family":"Prados-Carmona","sequence":"additional","affiliation":[{"name":"Servicio de Dermatolog\u00eda, Instituto Biosanitario de Granada, Ibs, Hospital Universitario San Cecilio, 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Rodriguez-Troncoso","sequence":"additional","affiliation":[{"name":"Servicio de Dermatolog\u00eda, Instituto Biosanitario de Granada, Ibs, Hospital Universitario San Cecilio, 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Raya-Alvarez","sequence":"additional","affiliation":[{"name":"Servicio de Reumatologia, Instituto Biosanitario de Granada, Ibs, Hospital Universitario San Cecilio, 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"key":"ref_1","first-page":"210","article-title":"Psoriasis, Psoriatic Arthritis, or Psoriatic Disease?","volume":"33","author":"Scarpa","year":"2006","journal-title":"J. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.2147\/CCID.S433367","article-title":"JAK Inhibitors in Psoriatic Disease","volume":"16","author":"Megna","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis Causes as Much Disability as Other Major Medical Diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/11597000-000000000-00000","article-title":"Nail Psoriasis: A Review","volume":"13","author":"Tan","year":"2012","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ad.2022.01.006","article-title":"Psoriasis ungueal","volume":"113","author":"Puig","year":"2022","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/jdv.14949","article-title":"Generalized Pustular Psoriasis: A Review and Update on Treatment","volume":"32","author":"Hoegler","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101692","DOI":"10.1016\/j.berh.2021.101692","article-title":"The Epidemiology of Psoriatic Arthritis: A Literature Review","volume":"35","author":"Karmacharya","year":"2021","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s12325-020-01585-7","article-title":"Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review","volume":"38","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic Arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2017.12.008","article-title":"Enthesitis: A Hallmark of Psoriatic Arthritis","volume":"48","author":"Kaeley","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101670","DOI":"10.1016\/j.berh.2021.101670","article-title":"Clinical Features of Psoriatic Arthritis","volume":"35","author":"Kishimoto","year":"2021","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/annrheumdis-2016-209853","article-title":"Axial Disease in Psoriatic Arthritis Study: Defining the Clinical and Radiographic Phenotype of Psoriatic Spondyloarthritis","volume":"76","author":"Jadon","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3899\/jrheum.091059","article-title":"Risk Factors for Axial Inflammatory Arthritis in Patients with Psoriatic Arthritis","volume":"37","author":"Chandran","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.semarthrit.2021.06.006","article-title":"Axial Involvement in Psoriatic Arthritis: An Update for Rheumatologists","volume":"51","author":"Poddubnyy","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1136\/annrheumdis-2017-212328","article-title":"Risk of Uveitis and Inflammatory Bowel Disease in People with Psoriatic Arthritis: A Population-Based Cohort Study","volume":"77","author":"Charlton","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"737079","DOI":"10.3389\/fmed.2021.737079","article-title":"Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey into the Immunologic Crosstalk","volume":"8","author":"Novelli","year":"2021","journal-title":"Front. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3899\/jrheum.150630","article-title":"Uveitis in Spondyloarthritis: An Overview","volume":"93","author":"Cantini","year":"2015","journal-title":"J. Rheumatol. Suppl."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10792-019-01183-9","article-title":"Ocular Manifestations of Rheumatic Diseases","volume":"40","author":"Szodoray","year":"2020","journal-title":"Int. Ophthalmol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1136\/annrheumdis-2014-205267","article-title":"Increased Burden of Inflammation over Time Is Associated with the Extent of Atherosclerotic Plaques in Patients with Psoriatic Arthritis","volume":"74","author":"Eder","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of Cardiovascular Morbidity in Patients with Psoriatic Arthritis: A Meta-Analysis of Observational Studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/acr.23171","article-title":"Incidence and Prevalence of Cardiovascular Risk Factors Among Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis","volume":"69","author":"Radner","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","article-title":"Obesity and Psoriatic Arthritis: A Narrative Review","volume":"7","author":"Kumthekar","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/BOR.0000000000000152","article-title":"Recognizing and Managing Comorbidities in Psoriatic Arthritis","volume":"27","author":"Ogdie","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe Psoriasis\u2014Oral Therapy with a New Retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2004.04.012","article-title":"Evaluating Psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician\u2019s Global Assessment","volume":"51","author":"Langley","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary Definition of Improvement in Rheumatoid Arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrrheum.2018.15","article-title":"Spondyloarthritis: Which Composite Measures to Use in Psoriatic Arthritis?","volume":"14","author":"Scarpa","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/ard.2009.117945","article-title":"Evaluation of the Appropriateness of Composite Disease Activity Measures for Assessment of Psoriatic Arthritis","volume":"69","author":"Stamm","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1136\/annrheumdis-2012-203073","article-title":"Disparity between Ultrasound and Clinical Findings in Psoriatic Arthritis","volume":"73","author":"Husic","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/ard.2011.155044","article-title":"Human Leucocyte Antigen Risk Alleles for Psoriatic Arthritis among Patients with Psoriasis","volume":"71","author":"Eder","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(21)00010-2","article-title":"Safety and Efficacy of Tofacitinib up to 48 Months in Patients with Active Psoriatic Arthritis: Final Analysis of the OPAL Balance Long-Term Extension Study","volume":"3","author":"Nash","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for Psoriatic Arthritis Refractory to Biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy and Safety Results from the 52-Week, Randomized, Double-Blinded, Placebo-Controlled Phase 3 POETYK PSO-1 Trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy and Safety Results from the 52-Week, Randomized, Double-Blinded, Phase 3 Program fOr Evaluation of TYK2 Inhibitor Psoriasis Second Trial","volume":"88","author":"Strober","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and Safety of Selective TYK2 Inhibitor, Deucravacitinib, in a Phase II Trial in Psoriatic Arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"CASPAR Study Group Classification Criteria for Psoriatic Arthritis: Development of New Criteria from a Large International Study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/10\/988\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:41:55Z","timestamp":1760107315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/10\/988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["diagnostics14100988"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics14100988","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,8]]}}}